Form 4: iBio Director Acquires Stock Options in Recent Transaction

iBio director Evert B. Schimmelpennink acquired 18,900 stock options on November 21, 2024, which vest monthly over twelve months.

Summary

• Evert B. Schimmelpennink, a director at iBio, Inc., acquired 18,900 stock options on November 21, 2024.
• These options have an exercise price of $2.45.
• The options vest pro rata on a monthly basis over twelve months, starting from the grant date.
• The options expire on November 20, 2034.
• The underlying security for these options is 18,900 shares of iBio common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction, which is neither particularly positive nor negative. It indicates a director's continued alignment with the company's interests.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of monthly over 12 months is a typical vesting period for stock options.
• The 10-year expiration period is also a standard term for stock options.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's belief in the company's future.

Key Dates

Keywords

stock options, insider trading, director, iBio, equity, options, vesting